Table 1.
Baseline characteristics of subjects for short-term analysis set.
| Demographics | Imidafenacin | Solifenacin | P-value | |
|---|---|---|---|---|
| Subjects | 17 | 18 | ||
| Age (years) | (Mean ± SD) | 70.2 ± 6.5 | 69.8 ± 7.7 | 0.8697a |
| <60, n (%) | 0 (0%) | 1 (5.6%) | ||
| ≥60, n (%) | 8 (47.1%) | 6 (33.3%) | ||
| ≥70, n (%) | 9 (52.9%) | 11 (61.1%) | ||
| Gender | ||||
| Male, n (%) | 10 (58.8%) | 12 (66.7%) | 0.7332b | |
| Female, n (%) | 7 (41.2%) | 6 (33.3%) | ||
| OABSS (total score) | (Mean ± SD) | 8.0 ± 2.0 | 8.7 ± 2.4 | 0.2989c |
| Severity of OABSS | ||||
| Mild, n (%) | 2 (11.8%) | 3 (16.7%) | 1.0000c | |
| Moderate, n (%) | 15 (88.2%) | 14 (77.8%) | ||
| Severe, n (%) | 0 (0%) | 1 (5.6%) | ||
| Postvoid residual volume (mL) | (Mean ± SD) | 14.2 ± 15.1 | 13.5 ± 11.4 | 0.8814a |
| Each urination volume (mL) | (Mean ± SD) | 141.7 ± 109.9 | 187.9 ± 160.8 | 0.3312a |
| Urination time (second) | (Mean ± SD) | 28.3 ± 19.8 | 27.4 ± 9.9 | 0.8749a |
| Qmax (mL/s) | (Mean ± SD) | 12.1 ± 7.4 | 14.2 ± 10.6 | 0.4925a |
| In male | ||||
| Prostate volume (mL) | (Mean ± SD) | 22.7 ± 11.6 | 25.3 ± 9.4 | 0.5661a |
| Use of α1 blocker, n (%) | 9 (90%) | 9 (75%) | 0.8328b |
Severity of OAB was defined as total OABSS score ≤5: mild; 6 to ≤11: moderate; ≥12: severe
a: Unpaired t-test, b: Fisher's exact test, c: Mann-Whitney U test, two-sided. SD: standard deviation.